Summary
25.33 0.15(0.60%)09/05/2024
Anika Therapeutics Inc. (ANIK)
Anika Therapeutics Inc. (ANIK)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.60 | -1.17 | -1.63 | -4.23 | -4.13 | 42.06 | -54.58 | 623.71 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 25.33 | |
| Open | 25.24 | |
| High | 25.35 | |
| Low | 24.74 | |
| Volume | 31,772 | |
| Change | 0.15 | |
| Change % | 0.60 | |
| Avg Volume (20 Days) | 31,525 | |
| Volume/Avg Volume (20 Days) Ratio | 1.01 | |
| 52 Week Range | 16.54 - 29.12 | |
| Price vs 52 Week High | -13.02% | |
| Price vs 52 Week Low | 53.14% | |
| Range | 0.36 | |
| Gap Up/Down | -0.14 | |
Fundamentals | ||
| Market Capitalization (Mln) | 375 | |
| EBIDTA | 3,990,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 2.2321 | |
| WallStreet Target Price | 31.00 | |
| Book Value | 14.0700 | |
| Earnings Per Share | -5.6400 | |
| EPS Estimate Current Quarter | -0.1900 | |
| EPS Estimate Next Quarter | 0.0600 | |
| EPS Estimate Current Year | -0.1500 | |
| EPS Estimate Next Year | 0.4100 | |
| Diluted EPS (TTM) | -5.6400 | |
| Revenues | ||
| Profit Marging | -0.4539 | |
| Operating Marging (TTM) | -0.2367 | |
| Return on asset (TTM) | -0.0181 | |
| Return on equity (TTM) | -0.3161 | |
| Revenue TTM | 169,260,992 | |
| Revenue per share TTM | 11.5400 | |
| Quarterly Revenue Growth (YOY) | 0.0690 | |
| Quarterly Earnings Growth (YOY) | -0.5050 | |
| Gross Profit (TTM) | 96,775,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 22.3214 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 1.7490 | |
| Revenue Enterprise Value | 1.9646 | |
| EBITDA Enterprise Value | -29.1505 | |
| Shares | ||
| Shares Outstanding | 14,828,500 | |
| Shares Float | 10,870,741 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.08 | |
| Insider (%) | 2.97 | |
| Institutions (%) | 94.52 | |
08/15 16:01 EST - globenewswire.com
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on August 1, 2024, Anika granted non-statutory stock options (“Options”) covering an aggregate of 8,850 shares of common stock at a per share exercise price of $26.29, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to two newly hired non-executive employees. The grants were made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, were approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), were made as a material inducement to the grantee's acceptance of employment with Anika as a component of the grantee's employment compensation.
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on August 1, 2024, Anika granted non-statutory stock options (“Options”) covering an aggregate of 8,850 shares of common stock at a per share exercise price of $26.29, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to two newly hired non-executive employees. The grants were made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, were approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), were made as a material inducement to the grantee's acceptance of employment with Anika as a component of the grantee's employment compensation.
08/11 01:49 EST - seekingalpha.com
Anika Therapeutics, Inc (ANIK) Q2 2024 Earnings Call Transcript
Anika Therapeutics, Inc (NASDAQ:ANIK ) Q2 2024 Earnings Call August 8, 2024 5:00 PM ET Company Participants Mark Namaroff - Vice President, Investor Relations Cheryl Blanchard - President and Chief Executive Officer Steve Griffin - Executive Vice President, Chief Financial Officer and Treasurer Conference Call Participants Jim Sidoti - Sidoti & Company Harrison Parsons - Stephens Mike Petusky - Barrington Research Operator Good afternoon, ladies and gentlemen, and welcome to Anika's Second Quarter 2024 Earnings Conference Call. [Operator Instructions] I will now turn the call over to Mark Namaroff, Vice President, Investor Relations, ESG and Corp. Communications.
Anika Therapeutics, Inc (ANIK) Q2 2024 Earnings Call Transcript
Anika Therapeutics, Inc (NASDAQ:ANIK ) Q2 2024 Earnings Call August 8, 2024 5:00 PM ET Company Participants Mark Namaroff - Vice President, Investor Relations Cheryl Blanchard - President and Chief Executive Officer Steve Griffin - Executive Vice President, Chief Financial Officer and Treasurer Conference Call Participants Jim Sidoti - Sidoti & Company Harrison Parsons - Stephens Mike Petusky - Barrington Research Operator Good afternoon, ladies and gentlemen, and welcome to Anika's Second Quarter 2024 Earnings Conference Call. [Operator Instructions] I will now turn the call over to Mark Namaroff, Vice President, Investor Relations, ESG and Corp. Communications.
08/08 19:36 EST - zacks.com
Anika Therapeutics (ANIK) Q2 Earnings Lag Estimates
Anika Therapeutics (ANIK) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to loss of $0.19 per share a year ago.
Anika Therapeutics (ANIK) Q2 Earnings Lag Estimates
Anika Therapeutics (ANIK) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to loss of $0.19 per share a year ago.
08/08 16:05 EST - globenewswire.com
Anika Reports Second Quarter 2024 Financial Results
Expanded Regenerative Solutions portfolio with full market release of the Integrity™ Implant System, a hyaluronic acid (HA)-based scaffold for rotator cuff and other tendon repairs, generating significant market demand
Anika Reports Second Quarter 2024 Financial Results
Expanded Regenerative Solutions portfolio with full market release of the Integrity™ Implant System, a hyaluronic acid (HA)-based scaffold for rotator cuff and other tendon repairs, generating significant market demand
08/05 16:01 EST - globenewswire.com
Anika to Participate in the Sidoti Virtual Investor Conference
BEDFORD, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will participate in the Sidoti Virtual Investor Conference on Thursday, August 15, 2024. Anika will host a virtual presentation with Q&A starting at 11:30am ET.
Anika to Participate in the Sidoti Virtual Investor Conference
BEDFORD, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will participate in the Sidoti Virtual Investor Conference on Thursday, August 15, 2024. Anika will host a virtual presentation with Q&A starting at 11:30am ET.
07/25 09:00 EST - globenewswire.com
Anika to Issue Second Quarter 2024 Financial Results on Thursday, August 8, 2024
BEDFORD, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its second quarter 2024 financial results after the close of the market on Thursday, August 8, 2024 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.
Anika to Issue Second Quarter 2024 Financial Results on Thursday, August 8, 2024
BEDFORD, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its second quarter 2024 financial results after the close of the market on Thursday, August 8, 2024 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.
07/11 08:30 EST - globenewswire.com
Anika Announces Full Market Release of the Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Scaffold for Rotator Cuff and Other Tendon Repairs
Integrity and its complete arthroscopic instrumentation platform are now fully available in the U.S., expanding Anika's proprietary hyaluronic acid (HA) regenerative portfolio
Anika Announces Full Market Release of the Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Scaffold for Rotator Cuff and Other Tendon Repairs
Integrity and its complete arthroscopic instrumentation platform are now fully available in the U.S., expanding Anika's proprietary hyaluronic acid (HA) regenerative portfolio
07/01 10:35 EST - globenewswire.com
Orthopedic Regenerative Surgical Products Market Size to Reach USD 6.6 Billion By 2033, at 4.4 CAGR: Insights by Dimension Market Research
Advancements and Projections in the Orthopedic Regenerative Surgical Products Market: Insights, Trends, Opportunities, and Recent Developments Advancements and Projections in the Orthopedic Regenerative Surgical Products Market: Insights, Trends, Opportunities, and Recent Developments
Orthopedic Regenerative Surgical Products Market Size to Reach USD 6.6 Billion By 2033, at 4.4 CAGR: Insights by Dimension Market Research
Advancements and Projections in the Orthopedic Regenerative Surgical Products Market: Insights, Trends, Opportunities, and Recent Developments Advancements and Projections in the Orthopedic Regenerative Surgical Products Market: Insights, Trends, Opportunities, and Recent Developments
05/28 16:05 EST - globenewswire.com
Anika Enters into Cooperation Agreement with Caligan Partners
Appoints Joseph Capper and William Jellison to Board of Directors Announces New $40 Million Share Repurchase Program
Anika Enters into Cooperation Agreement with Caligan Partners
Appoints Joseph Capper and William Jellison to Board of Directors Announces New $40 Million Share Repurchase Program
05/08 23:36 EST - seekingalpha.com
Anika Therapeutics, Inc. (ANIK) Q1 2024 Earnings Call Transcript
Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q1 2024 Earnings Conference Call May 8, 2024 5:30 PM ET Company Participants Mark Namaroff - Vice President of Investor Relations, ESG and Corporate Communications Cheryl Blanchard - President and Chief Executive Officer Michael Levitz - Executive Vice President and Chief Financial Officer Conference Call Participants George Sellers - Stephens Inc. James Sidoti - Sidoti & Company, LLC Mike Petusky - Barrington Research Operator Good evening, ladies and gentlemen, and welcome to Anika's First Quarter 2024 Earnings Conference Call. At this time, all lines are in a listen-only mode.
Anika Therapeutics, Inc. (ANIK) Q1 2024 Earnings Call Transcript
Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q1 2024 Earnings Conference Call May 8, 2024 5:30 PM ET Company Participants Mark Namaroff - Vice President of Investor Relations, ESG and Corporate Communications Cheryl Blanchard - President and Chief Executive Officer Michael Levitz - Executive Vice President and Chief Financial Officer Conference Call Participants George Sellers - Stephens Inc. James Sidoti - Sidoti & Company, LLC Mike Petusky - Barrington Research Operator Good evening, ladies and gentlemen, and welcome to Anika's First Quarter 2024 Earnings Conference Call. At this time, all lines are in a listen-only mode.
05/08 16:08 EST - globenewswire.com
Anika Announces CFO Transition
Steve Griffin Appointed Chief Financial Officer, Effective June 3, 2024 Steve Griffin Appointed Chief Financial Officer, Effective June 3, 2024
Anika Announces CFO Transition
Steve Griffin Appointed Chief Financial Officer, Effective June 3, 2024 Steve Griffin Appointed Chief Financial Officer, Effective June 3, 2024
05/08 16:05 EST - globenewswire.com
Anika Reports First Quarter 2024 Financial Results
Revenue up 7% on growing demand and favorable order timing; On-track for 2024 revenue guidance Cost reduction initiatives complete; On-track to achieve 2024 adjusted EBITDA guidance of $25-30 million, up over 75% at the midpoint BEDFORD, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financial results for its first quarter ended March 31, 2024.
Anika Reports First Quarter 2024 Financial Results
Revenue up 7% on growing demand and favorable order timing; On-track for 2024 revenue guidance Cost reduction initiatives complete; On-track to achieve 2024 adjusted EBITDA guidance of $25-30 million, up over 75% at the midpoint BEDFORD, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financial results for its first quarter ended March 31, 2024.
04/18 16:01 EST - globenewswire.com
Anika to Issue First Quarter 2024 Financial Results on Wednesday, May 8, 2024
BEDFORD, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its first quarter 2024 financial results after the close of the market on Wednesday, May 8, 2024 and hold its investor conference call on the same day, at 5:30 p.m. ET to discuss its financial results and business highlights.
Anika to Issue First Quarter 2024 Financial Results on Wednesday, May 8, 2024
BEDFORD, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its first quarter 2024 financial results after the close of the market on Wednesday, May 8, 2024 and hold its investor conference call on the same day, at 5:30 p.m. ET to discuss its financial results and business highlights.
04/02 08:00 EST - globenewswire.com
Anika to Participate in the 23rd Annual Needham Virtual Healthcare Conference
BEDFORD, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will participate in the 23rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024. Anika will host a virtual presentation with Q&A starting at 2:15pm ET.
Anika to Participate in the 23rd Annual Needham Virtual Healthcare Conference
BEDFORD, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will participate in the 23rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024. Anika will host a virtual presentation with Q&A starting at 2:15pm ET.
03/13 19:17 EST - seekingalpha.com
Anika Therapeutics, Inc. (ANIK) Q4 2023 Earnings Call Transcript
Anika Therapeutics, Inc. (ANIK) Q4 2023 Earnings Call Transcript
Anika Therapeutics, Inc. (ANIK) Q4 2023 Earnings Call Transcript
Anika Therapeutics, Inc. (ANIK) Q4 2023 Earnings Call Transcript
03/13 16:05 EST - globenewswire.com
Anika Reports Fourth Quarter and Year-End 2023 Financial Results
Revenue growth and adjusted EBITDA1 exceeded expectations in the fourth quarter and full year OA Pain Management achieved record annual revenues of $102 million, up 11% in 2023 Announces cost reduction initiatives providing annualized savings of approximately $10 million Anika positioned to generate adjusted EBITDA1 of $25 to $30 million in 2024, up over 75% at the midpoint, representing an adjusted EBITDA1 margin of at least 15% BEDFORD, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financial results for its fourth quarter and full year ended December 31, 2023.
Anika Reports Fourth Quarter and Year-End 2023 Financial Results
Revenue growth and adjusted EBITDA1 exceeded expectations in the fourth quarter and full year OA Pain Management achieved record annual revenues of $102 million, up 11% in 2023 Announces cost reduction initiatives providing annualized savings of approximately $10 million Anika positioned to generate adjusted EBITDA1 of $25 to $30 million in 2024, up over 75% at the midpoint, representing an adjusted EBITDA1 margin of at least 15% BEDFORD, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financial results for its fourth quarter and full year ended December 31, 2023.